Recently, PhRMA hosted a teleconference to provide an update on our member companies’ around-the-clock efforts in developing treatments and vaccines for COVID-19, a disease caused by a novel coronavirus. PhRMA president and CEO Steve Ubl led the conversation and was joined by Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, Clement Lewin, Ph.D., associate vice president Head BARDA Office and NV Stakeholder Engagement, Sanofi, Thomas Breuer, MD, MSc., senior vice president, chief medical officer, GSK Vaccines, Julie Kim, president of Plasma-Derived Therapies, Takeda and Daniel Skovronsky, Lilly chief scientific officer and president, Lilly Research Laboratories. The participants represent a snapshot of the more than half of PhRMA members who are engaged in research and development towards combatting COVID-19.
The following is a collection of recent media coverage spotlighting how PhRMA’s members are working to combat COVID-19:
PhRMA is working with governments and insurers to ensure that when new treatments and vaccines are approved, they will be available and affordable for patients.
PhRMA member companies recently established core principles that outline our industry’s commitment to beating coronavirus. Principles include:
- Rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies.
- Dedicating our top scientists and using our investments in new technologies to speed the development of safe and effective vaccines.
- Coordinating with the governments and diagnostic partners to increase COVID-19 testing capability and capacity.
Our industry will continue to do everything we can to beat this virus as quickly and safely as possible.
Learn more at PhRMA.org/coronavirus.